Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance)

PURPOSE: Lenalidomide and rituximab (LR) are active agents in follicular lymphoma (FL). Combination regimens have not been previously assessed in randomized studies. PATIENTS AND METHODS: The Cancer and Leukemia Group B (Alliance) 50401 trial is a randomized phase II trial studying rituximab (375 mg...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Clin Oncol
Main Authors: Leonard, John P., Jung, Sin-Ho, Johnson, Jeffrey, Pitcher, Brandelyn N., Bartlett, Nancy L., Blum, Kristie A., Czuczman, Myron, Giguere, Jeffrey K., Cheson, Bruce D.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Clinical Oncology 2015
Assuntos:
ORIGINAL REPORTS
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4622102/
https://ncbi.nlm.nih.gov/pubmed/26304886
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.59.9258
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares